Patents by Inventor Robert Hugh Bradbury

Robert Hugh Bradbury has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • [1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases
    Publication number: 20230035133
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and n have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use as anti-proliferative and/or cell-killing agents.
    Type: Application
    Filed: June 29, 2022
    Publication date: February 2, 2023
    Applicant: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, Alfred Arthur Rabow, Michael James Waring, James Francis McCabe, Steven Christopher Glossop, Arshed Mahmood, Zoe Ann Cotter
  • [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
    Patent number: 11407755
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and n have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use as anti-proliferative and/or cell-killing agents.
    Type: Grant
    Filed: July 16, 2020
    Date of Patent: August 9, 2022
    Assignee: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, Alfred Arthur Rabow, Michael James Waring, James Francis McCabe, Steven Christopher Glossop, Arshed Mahmood, Zoe Ann Cotter
  • 1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES
    Publication number: 20210107905
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and n have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use as anti-proliferative and/or cell-killing agents.
    Type: Application
    Filed: July 16, 2020
    Publication date: April 15, 2021
    Inventors: Robert Hugh BRADBURY, Alfred Arthur RABOW, Michael James WARING, James Francis MCCABE, Steven Christopher GLOSSOP, Arshed MAHMOOD, Zoe Ann COTTER
  • [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases
    Patent number: 10766905
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and n have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use as anti-proliferative and/or cell-killing agents.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: September 8, 2020
    Assignee: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, Alfred Arthur Rabow, Michael James Waring, James Francis McCabe, Steven Christopher Glossop, Arshed Mahmood, Zoe Ann Cotter
  • [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES
    Publication number: 20200055861
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and n have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use as anti-proliferative and/or cell-killing agents.
    Type: Application
    Filed: August 1, 2019
    Publication date: February 20, 2020
    Inventors: Robert Hugh Bradbury, Alfred Arthur Rabow, Michael James Waring, James Francis McCabe, Steven Christopher Glossop, Arshed Mahmood, Zoe Ann Cotter
  • [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases
    Patent number: 10407432
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and n have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use as anti-proliferative and/or cell-killing agents.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: September 10, 2019
    Assignee: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, Alfred Arthur Rabow, Michael James Waring, James Francis McCabe, Steven Christopher Glossop, Arshed Mahmood, Zoe Ann Cotter
  • CHEMICAL COMPOUNDS
    Publication number: 20190038607
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 to R5 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: October 12, 2018
    Publication date: February 7, 2019
    Applicant: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, David Buttar, Christopher De Savi, Craig Samuel Donald, Richard Albert Norman, Alfred Arthur Rabow, Gordon Stuart Currie, Heather Redfearn, Nadim Akhtar, Helen Elizabeth Williams, Matthew Osborne, Neda Yavari
  • Chemical compounds
    Patent number: 10130617
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 to R5 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: November 20, 2018
    Assignee: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, David Buttar, Christopher De Savi, Craig Samuel Donald, Richard Albert Norman, Alfred Arthur Rabow, Gordon Stuart Currie, Heather Redfearn, Nadim Akhtar, Helen Elizabeth Williams, Matthew Osborne, Neda Yavari
  • [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES
    Publication number: 20180230158
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and n have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use as anti-proliferative and/or cell-killing agents.
    Type: Application
    Filed: April 11, 2018
    Publication date: August 16, 2018
    Applicant: AstraZeneca AB
    Inventors: Robert Hugh BRADBURY, Alfred Arthur Rabow, Michael James Waring, James Francis McCabe, Steven Christopher Glossop, Arshed Mahmood, Zoe Ann Cotter
  • [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases
    Patent number: 9944650
    Abstract: The invention concerns compounds of Formula (I) (Formula (I)) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and n have any of the meanings defined herein before in the description; processes for their preparation, pharmaceutical compositions containing them and their use as anti-proliferative and/or cell-killing agents.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: April 17, 2018
    Assignee: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, Alfred Arthur Rabow, Michael James Waring, James Francis McCabe, Steven Christopher Glossop, Arshed Mahmood, Zoe Ann Cotter
  • CHEMICAL COMPOUNDS
    Publication number: 20170326115
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 to R5 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: February 28, 2017
    Publication date: November 16, 2017
    Applicant: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, David Buttar, Christopher De Savi, Craig Samuel Donald, Richard Albert Norman, Alfred Arthur Rabow, Gordon Stuart Currie, Heather Redfearn, Nadim Akhtar, Helen Elizabeth Williams, Matthew Osborne, Neda Yavari
  • [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES
    Publication number: 20170210747
    Abstract: The invention concerns compounds of Formula (I) (Formula (I)) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and n have any of the meanings defined herein before in the description; processes for their preparation, pharmaceutical compositions containing them and their use as anti-proliferative and/or cell-killing agents.
    Type: Application
    Filed: July 24, 2015
    Publication date: July 27, 2017
    Applicant: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, Alfred Arthur Rabow, Michael James Waring, James Francis McCabe, Steven Christopher Glossop, Arshed Mahmood, Zoe Ann Cotter
  • Chemical compounds
    Patent number: 9616050
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 to R5 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: April 11, 2017
    Assignee: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, David Buttar, Christopher De Savi, Craig Samuel Donald, Richard Albert Norman, Alfred Arthur Rabow, Gordon Stuart Currie, Heather Redfearn, Nadim Akhtar, Helen Elizabeth Williams, Matthew Osborne, Neda Yavari
  • Chemical Compounds
    Publication number: 20160136140
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 to R5 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: August 31, 2015
    Publication date: May 19, 2016
    Applicant: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, David Buttar, Christopher De Savi, Craig Samuel Donald, Richard Albert Norman, Alfred Arthur Rabow, Gordon Stuart Currie, Heather Redfearn, Nadim Akhtar, Helen Elizabeth Williams, Matthew Osborne, Neda Yavari
  • Chemical compounds
    Patent number: 9155727
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 to R5 have any of the meanings defined hereinbefore in the description: processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: October 13, 2015
    Assignee: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, David Buttar, Christopher De Savi, Craig Samuel Donald, Richard Albert Norman, Alfred Arthur Rabow, Gordon Stuart Currie, Heather Marie Redfearn, Nadim Akhtar, Helen Elizabeth Williams, Matthew Osborne, Neda Yavari
  • CHEMICAL COMPOUNDS
    Publication number: 20140357661
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 to R5 have any of the meanings defined hereinbefore in the description: processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: May 27, 2014
    Publication date: December 4, 2014
    Applicant: ASTRAZENECA AB
    Inventors: Robert Hugh BRADBURY, David BUTTAR, Christopher DE SAVI, Craig Samuel DONALD, Richard Albert NORMAN, Alfred Arthur RABOW, Gordon Stuart CURRIE, Heather Marie REDFEARN, Nadim AKHTAR, Helen Elizabeth WILLIAMS, Matthew OSBORNE, Neda YAVARI
  • CHEMICAL COMPOUNDS - 643
    Publication number: 20130203714
    Abstract: The invention concerns bicyclic compounds of Formula I wherein R1, R2, L1, L2, J, Y, k, n, p and r are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the treatment of androgen-receptor associated conditions, particularly prostate cancer.
    Type: Application
    Filed: August 1, 2012
    Publication date: August 8, 2013
    Applicant: ASTRAZENECA R&D
    Inventors: Robert Hugh Bradbury, Gregory Richard Carr, Alfred Arthur Rabow, Srinivasa Rao Korupoju, Harikrishna Tumma
  • 4-anilino quinazoline derivatives as antiproliferative agents
    Patent number: 8399667
    Abstract: The invention concerns quinazoline derivatives of Formula (I) wherein each of Q1, Z, R1 and Q2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.
    Type: Grant
    Filed: February 16, 2010
    Date of Patent: March 19, 2013
    Assignee: Astrazeneca AB
    Inventors: Robert Hugh Bradbury, Laurent Francois Andre Hennequin, Jason Grant Kettle
  • QUINAZOLINE DERIVATIVES
    Publication number: 20130005727
    Abstract: The invention concerns quinazoline derivatives of Formula I wherein each of Q1, Z, R1 and Q2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.
    Type: Application
    Filed: September 10, 2012
    Publication date: January 3, 2013
    Applicant: ASTRAZENECA AB
    Inventors: Robert Hugh BRADBURY, Laurent Francois Andre HENNEQUIN, Jason Grant KETTLE
  • QUINAZOLINE DERIVATIVES
    Publication number: 20120329795
    Abstract: The invention concerns quinazoline derivatives of Formula I: wherein each of R1, X1, R2, R3, R5, n and m have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases.
    Type: Application
    Filed: September 10, 2012
    Publication date: December 27, 2012
    Inventors: Laurent Francois Andre Hennequin, Bernard Christophe Barlaam, Robert Hugh Bradbury